Aurobindo acquires four biosimilars from TL Biopharmaceutical
HYDERABAD, India — Aurobindo Pharma acquired four cell culture derived biosimilar products from TL Biopharmaceutical.
As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally.
Regulatory filing for these products is intended in the period 2020-22.
Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple-cancers including metastatic colon or rectal cancer, non-squamous and non-small cell lung cancers.
According to India-based Aurobindo, “this transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape.”
“We are impressed with TL’s product development as these are developed to the highest standards of biosimilarity,” said N. Govindarajan, managing director of Aurobindo Pharma. “This acquisition is in-line with our strategy of investing in complex products and is an important first step toward establishing Aurobindo’s global biosimilars portfolio.”